Sign in Create account
Sign in and upgrade to a paid plan to export price history as CSV.

Alpa Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ALPA BSE: 532878
₹59.51
▼ -0.25 (-0.42%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
52/100
Moderate
Valuation
63/100
Fairly Valued
Momentum
47/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹125 Cr
PE (TTM)
28.3
Industry median 36.1 (152 companies)
Price to Book
0.7
PEG (TTM)
-0.3
Institutions holding %
0.42%
FII + DII, latest filed period
Piotroski Score
4
Relative return vs Nifty50, qtr %
-5.0
Relative return vs Sector, qtr %
-13.6
Free Cash Flow
₹8 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-90.71%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-45.83%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
1.21%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-91.19%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
25.22%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
4.01
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.01
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
17.71
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
4.34%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
4.81%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
5.65%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
4.81%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
8.42%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
6.26%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 4)
  • Yes Debt to equity is below 0.5 (0.01)
  • No Return on equity is 15% or more (6.3%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 4 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.4%
Low 59.2500 · High 61.5000
1W return
-1.5%
Low 58.3000 · High 61.6000
1M return
-5.1%
Low 55.7600 · High 65.0000
52W return
-33.0%
Low 46.1000 · High 93.8500
Lifetime High ₹139.2000 (Sept. 30, 2024)
Lifetime Low ₹5.1000 (June 13, 2013)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
59.6
10D
59.9
20D
60.8
50D
62.9
100D
64.9
200D
67.3

Delivery and volume

Day avg. delivery
77.9%
Week avg. delivery
30.1%
Month avg. delivery
46.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

60.09
Pivot
First resistance60.92
Second resistance62.34
Third resistance63.17
First support58.67
Second support57.84
Third support56.42
Day RSI40.3
Day MFI32.3
Day MACD-1.19
Day MACD signal-1.20

Beta

1M0.09
3M0.35
1Y1.03
3Y1.09

Price change analysis

↓ -5.1%
Over 1 Month
LowHigh
55.7665.00
↓ -13.6%
Over 3 Months
LowHigh
55.7678.89
↑ 18.5%
Over 6 Months
LowHigh
48.6078.89
↓ -33.0%
Over 1 Year
LowHigh
46.1093.85
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 28.3 (own history: 6.5–32.2)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹24 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹0.5200

Ranks #135 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter57.19%
  • FII/FPI0.35%
  • Public42.39%

Largest holders

NameCategoryShares %Shares
PARESH CHAWLAPromoter34.2600%7208210
SHITUL SHAHPromoter10.1500%2134780
BAKULESH SHAHPromoter4.8800%1026600
RIMA SHAHPromoter3.6800%775200
RUPAL SHAHPromoter2.6600%558780

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 57.19% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 0.38% to 0.35% in Jun 2026 qtr

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 29 insider trades, 21 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
7 Mar 2026 VINIT SHAH Immediate relative Buy 0 ₹0
7 Mar 2026 BAKULESH CHANDULAL SHAH HUF Promoter Sell 0 ₹0
26 Jun 2025 Mr. Shitul Shah Promoter Buy 0 ₹0
26 Jun 2025 Mr. Pravin shah Promoter Sell 0 ₹0
19 Jun 2025 Mr. Shitul Shah Promoter Buy 0 ₹0
19 Jun 2025 Mr. Pravin shah Promoter Sell 0 ₹0
17 Jun 2025 Mahendra Singh Chawla Promoter Sell 0 ₹0
17 Jun 2025 Asha Chawla Promoter Sell 0 ₹0
17 Jun 2025 Paresh Chawla Promoter Buy 0 ₹0
6 Mar 2022 SHITUL SHAH Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 148 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
30 Sep 2024 QE SECURITIES LLP Bulk Buy 203,805 139.7600 NSE
30 Sep 2024 QE SECURITIES LLP Bulk Sell 200,761 139.7500 NSE
30 Sep 2024 PRADEEP KUMAR JAIN Bulk Sell 125,141 138.8100 NSE
30 Sep 2024 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Buy 183,809 138.6900 NSE
30 Sep 2024 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 183,809 138.7900 NSE
30 Sep 2024 MUDUPULAVEMULA SURENDRANADHA REDDY Bulk Buy 169,278 139.2100 NSE
30 Sep 2024 MUDUPULAVEMULA SURENDRANADHA REDDY Bulk Sell 169,278 139.3500 NSE
30 Sep 2024 MICROCURVES TRADING PRIVATE LIMITED Bulk Sell 122,111 139.5600 NSE
30 Sep 2024 MICROCURVES TRADING PRIVATE LIMITED Bulk Buy 122,111 139.5400 NSE
30 Sep 2024 HRTI PRIVATE LIMITED Bulk Buy 155,746 139.4200 NSE

All bulk and block deals →

Corporate Actions

Full history (17 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
20 Sep 2024OTHERAnnual General Meeting
21 Sep 2023OTHERAnnual General Meeting
20 Sep 2022OTHERAnnual General Meeting
20 Sep 2021OTHER Annual General Meeting
18 Sep 2020OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
14 Aug 2026 Financial Results Yes
29 May 2026 Financial Results Yes
11 Feb 2026 Financial Results Yes
14 Nov 2025 Financial Results Yes
13 Aug 2025 Financial Results/Other business matters Yes

Corporate Announcements

All 310 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
3 Oct 2026 Shareholders meeting Alpa Laboratories Limited has submitted the Exchange a copy Srutinizers report of undefined held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.
30 Sep 2026 AGM/EGM Alpa Laboratories Ltd - 532878 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 Shareholders meeting Alpa Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
29 Sep 2026 Trading Window Alpa Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
29 Sep 2026 Insider Trading / SAST Alpa Laboratories Ltd - 532878 - Closure of Trading Window
17 Sep 2026 Appointment Alpa Laboratories Limited has informed the Exchange regarding Appointment of Ms Ms. Diksha Jaswani as Company Secretary of the company w.e.f. September 17, 2026.
7 Sep 2026 Record Date Alpa Laboratories Limited has informed the Exchange that Record date for the purpose of Meeting is 22-Sep-2026.
7 Sep 2026 Appointment Alpa Laboratories Limited has informed the Exchange regarding Appointment of Mrs RADHIKA as Non- Execut of the company w.e.f. September 05, 2026.
13 Aug 2026 Outcome of Board Meeting Alpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
11 Aug 2026 Updates Alpa Laboratories Limited has informed the Exchange regarding 'clarification board meeting date'.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.01)
  • Comfortable interest coverage (17.7x)
  • Strong revenue growth YoY (25.2%)

Weaknesses

  • Low Return on Equity (6.3%)
  • Thin net profit margin (4.3%)
  • Declining profit YoY (-91.2%)

Opportunities

  • Trading below book value (PB 0.67)

Threats

  • Down 33.0% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Alpa Laboratories Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.